Bayer Aktienges ADR (OP: BAYRY )

4.870 -0.010 (-0.20%)

Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist

Price and Volume

Volume	834,178
Open	4.860
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	4.880
Today's Range	4.790 - 5.140
52wk Range	4.790 - 9.790
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study

December 17, 2024

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.

Via Benzinga

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

November 25, 2024

FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.

Via Benzinga

Performance

YTD	-48.08%	-48.08%
1 Month	-6.53%	-6.53%
3 Month	-40.02%	-40.02%
6 Month	-30.53%	-30.53%
1 Year	-45.89%	-45.89%

More News

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

November 19, 2024

Via Benzinga

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

November 16, 2024

Via MarketBeat

Bayer Seeks European Approval For Its Menopause Drug

October 15, 2024

Via Benzinga

Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide

October 14, 2024

Via Benzinga

Week In Review: Zenas Raises $259 Million In IPO

September 28, 2024

Via Talk Markets

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

September 23, 2024

Via Investor's Business Daily

“Signing Day Sports, Inc. (NYSE American: SGN) Soars in Pre-Market on Acquisition News – see more penny stocks inside….”

September 19, 2024

Via AB Newswire

Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study

September 16, 2024

Via Benzinga

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer

September 10, 2024

Via Benzinga

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

August 30, 2024

Via Benzinga

BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024

August 06, 2024

Via InvestorPlace

Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer

July 25, 2024

Via Benzinga

ScottsMiracle-Gro Stock Blooms After Investor Day Optimism

July 23, 2024

Via MarketBeat

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs

July 08, 2024

Via InvestorPlace

3 Small-Cap Stocks With Explosive 2X Growth Potential

July 08, 2024

Via InvestorPlace

Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M

June 05, 2024

Via Benzinga

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership

June 01, 2024

Via Talk Markets

European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?

May 27, 2024

Via Benzinga

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February

May 24, 2024

Via Benzinga

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval

May 17, 2024

Via Benzinga

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game

May 16, 2024

Via Benzinga

BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024

May 14, 2024

Via InvestorPlace

From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch

May 10, 2024

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.